ClinicalTrials.gg
CompletedNCT04149002Updated Nov 2, 2022Results posted

Improving the Clinical Encounter to Enhance Delivery of an Individualized Prematurity Prevention Plan

An interventional study of Intervention Arm Weekly IP3 text messages and Active Control Arm General pregnancy text messages in Preterm Birth, sponsored by Duke University. Completed at 1 site in United States. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-11-02.

Sponsored by Duke University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Study summary

The purpose of this study is to pilot an intervention that was developed to improve uptake and adhere to an Individualized Prematurity Prevention Plan (IP3) for preterm birth prevention. Non-Hispanic Black (NHB) women are at higher risk for preterm birth compared to other racial and ethnic groups. Building on qualitative data from NHB women with input from a multidisciplinary stakeholder group, a patient-centered intervention was developed to improve uptake and adherence to an IP3 in NHB women.

Read the detailed description

The study team will pilot test the intervention via a pilot randomized controlled trial. 60 pregnant NHB women will be recruited who have a history of singleton preterm birth and are currently pregnant with a singleton gestation. Consenting participants will be randomized to the intervention or an active control. The intervention includes: 1) an informational narrated powerpoint presentation that reviews the logistical details of the IP3, 2) structured encouragement via text messages and 3) employment law education sheet. The powerpoints will also be available for review on our you-tube channel for intervention patients. The active control arm includes: 1) a narrated powerpoint describing the Duke Prematurity Prevention Program and 2) text messages with general pregnancy information (i.e. it is safe to take Tylenol in pregnancy). At study intake, we will collect demographic data (age, self-described race, pregnancy history, social history, pregnancy-related anxiety scale, interpersonal processes of care and maternal social support index.

The team will collect feedback on the intervention based on an intake questionnaire and an exit interview.

Information will also be collected on adherence to the IP3 based on review of the participant's medical record. The primary aim of the study is to evaluation feasibility and acceptability. These endpoints will be measured via enrollment and participant feedback during the exit interview.

02

Conditions studied

  • Preterm Birth

Browse trials for

03

In context

Premature Birth

2,610 studies on the registry are indexed under Premature Birth; 507 are open to participants now.

This study's enrollment of 30 is below the median of 84 across 1,722 interventional studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Duke University is the lead sponsor of 2,058 studies on the registry; 274 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 165 (81%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • self described race as Non-Hispanic Black
  • history of prior singleton preterm delivery (before 37 weeks gestation)
  • current singleton gestation

Exclusion criteria

Exclusion Criteria:

  • women with anomalous fetuses
  • age below 18]
  • non-English speaking
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Other
    Intervention Arm: Weekly IP3 text messages

    * A narrated powerpoint presentation describing the logistical details and medical rationale for components of the IP3. Participants will view the chapters of the presentation that are relevant to their specific IP3. There are a total of 4 possible chapters (lifestyle modifications, cervix length screening/cerclage, progesterone therapy, low dose aspirin). Each chapter of the presentation is \~ 10 - 15 min in length. Each chapter also includes a 4- 5 questions pre-test and the same questions are delivered as a post-test after the presentation. * Print materials including a letter explaining the importance of prenatal care for preterm birth prevention to employers. * Text messages sent weekly to encourage the patient to continue with their IP3 and provide basic pregnancy information * Formal letter of encouragement from provider at 28 weeks gestation

    Behavioral: Intervention Arm Weekly IP3 text messages

  • Active comparator
    Control Arm: General pregnancy text messages

    * a pre-intervention questionnaire * a narrated powerpoint with general information about the clinic * a post-presentation questionnaire * text messages sent approximately weekly with general pregnancy information (e.g. today your baby is about the size of an apple) * an exit interview

    Other: Active Control Arm General pregnancy text messages

Interventions

  • BehavioralIntervention Arm Weekly IP3 text messages

    Subjects will be provided with a pre and post intervention survey, in addition to a narrated Powerpoint presentation focusing on the logistics of their IP3. Subjects will also receive weekly automated text messages to encourage adherence to the need for their IP3.

  • OtherActive Control Arm General pregnancy text messages

    Subjects will be given pre and post pre questionnaires, in addition to a narrated Powerpoint presentation about the Clinic. Subjects will also be sent weekly text messages with general pregnancy information.

06

What researchers measure

Primary outcomes

  1. Feasibility as Measured by Number of Recruited Eligible Patients Enrolled

    Enrollment target of 30% of eligible patients recruited.

    Time frame: study duration (approximately 14 months)

  2. Acceptability as Measured by Number of Participants Who Completed the Study

    Completion target of 80% participants retained in study protocol.

    Time frame: study duration (approximately 14 months)

Secondary outcomes

  1. IP3 Adherence as Measured by Number of Participants With Patient and EMR (Electronic Medical Record) Report of Medication Compliance

    Time frame: approximately 1 year

  2. Pregnancy Specific Anxiety (PSA)

    Pregnancy specific anxiety is a 4-question scale. Each question can be answered on a range of 1 to 5. Scores were averaged to produce one mean PSA score ranging from 1-5. Higher scores are negative and denote increased anxiety.

    Time frame: baseline, 28 weeks

  3. Interpersonal Process of Care (IPC-18) at Protocol Completion - Communication Domain

    The IPC is an 18-question questionnaire that asks participants about their experience with receiving care within a specific clinic (in this case the Duke Perinatal Durham Clinic). All IPC items use an identical set of response options: 1='never'; 2='rarely'; 3='sometimes'; 4='usually'; 5='always.' Item responses are averaged, not summed; thus, scores have a possible range of 1-5. All scales are scored so that higher scores indicate higher frequency of the labeled interpersonal process: Lack of clarity (higher scores are negative), Elicits concern (higher scores are positive), and Explain results (higher scores are positive).

    Time frame: protocol completion (approximately 1 year)

  4. Interpersonal Process of Care (IPC-18) at Protocol Completion - Decision Making Domain

    The IPC is an 18-question questionnaire that asks participants about their experience with receiving care within a specific clinic (in this case the Duke Perinatal Durham Clinic). All IPC items use an identical set of response options: 1='never'; 2='rarely'; 3='sometimes'; 4='usually'; 5='always.' Item responses are averaged, not summed; thus, scores have a possible range of 1-5. All scales are scored so that higher scores indicate higher frequency of the labeled interpersonal process: Decision Making (higher scores are positive, denoting more collaborative decision making between the clinician and patient).

    Time frame: protocol completion (approximately 1 year)

  5. Interpersonal Process of Care (IPC-18) at Protocol Completion - Interpersonal Style Domain

    The IPC is an 18-question questionnaire that asks participants about their experience with receiving care within a specific clinic (in this case the Duke Perinatal Durham Clinic). All IPC items use an identical set of response options: 1='never'; 2='rarely'; 3='sometimes'; 4='usually'; 5='always.' Item responses are averaged, not summed; thus, scores have a possible range of 1-5. All scales are scored so that higher scores indicate higher frequency of the labeled interpersonal process: Emotional support (higher scores are positive), Discrimination due to race/ethnicity (higher scores are negative), Disrespectful to office staff (higher scores are negative).

    Time frame: protocol completion (approximately 1 year)

  6. Change in Maternal Social Support Scale (MSSS)

    The MSSS is a six-question scale that quantifies a pregnant woman's social support. Social factors (lack of family support, low friendship network, lack of help from spouse/partner, conflict with spouse/partner, feeling controlled by spouse/partner, and feeling unloved by spouse/partner) are combined in a 6-item self-report 5-point Likert scale. The total possible score for the scale is between 6 and 30, with higher scores indicating increased support.

    Time frame: baseline to protocol completion (approximately 1 year)

  7. Gestational Age at Delivery in Weeks

    Time frame: approximately 40 weeks

  8. Birth Weight in Grams

    Time frame: approximately 40 weeks

  9. Number of Neonates Admitted to the Newborn Intensive Care Unit (NICU)

    Time frame: approximately 40 weeks

  10. Length of Delivery Hospital Admission in Days

    Time frame: approximately 40 weeks

07

Results

Posted Nov 2, 2022

Participant flow

Participant flow — Overall Study
MilestoneIntervention Arm: Weekly IP3 Text MessagesControl Arm: General Pregnancy Text Messages
Started1416
Completed1216
Not completed20
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryFeasibility as Measured by Number of Recruited Eligible Patients Enrolled

Enrollment target of 30% of eligible patients recruited.

Time frame:
study duration (approximately 14 months)
Reported as:
Count of participants · Participants
Feasibility as Measured by Number of Recruited Eligible Patients Enrolled
ParticipantsEligible Patients Recruited
Feasibility as Measured by Number of Recruited Eligible Patients Enrolled30
PrimaryAcceptability as Measured by Number of Participants Who Completed the Study

Completion target of 80% participants retained in study protocol.

Time frame:
study duration (approximately 14 months)
Reported as:
Count of participants · Participants
Acceptability as Measured by Number of Participants Who Completed the Study
ParticipantsIntervention Arm: Weekly IP3 Text MessagesControl Arm: General Pregnancy Text Messages
Acceptability as Measured by Number of Participants Who Completed the Study1216
SecondaryIP3 Adherence as Measured by Number of Participants With Patient and EMR (Electronic Medical Record) Report of Medication Compliance
Time frame:
approximately 1 year
Reported as:
Count of participants · Participants
IP3 Adherence as Measured by Number of Participants With Patient and EMR (Electronic Medical Record) Report of Medication Compliance
ParticipantsIntervention Arm: Weekly IP3 Text MessagesControl Arm: General Pregnancy Text Messages
IP3 Adherence as Measured by Number of Participants With Patient and EMR (Electronic Medical Record) Report of Medication Compliance13
SecondaryPregnancy Specific Anxiety (PSA)

Pregnancy specific anxiety is a 4-question scale. Each question can be answered on a range of 1 to 5. Scores were averaged to produce one mean PSA score ranging from 1-5. Higher scores are negative and denote increased anxiety.

Time frame:
baseline, 28 weeks
Reported as:
Mean · score on a scale
Pregnancy Specific Anxiety (PSA)
score on a scaleIntervention Arm: Weekly IP3 Text MessagesControl Arm: General Pregnancy Text Messages
Baseline2.6 ± 1.02.4 ± 0.9
28 Weeks2.3 ± 0.92.3 ± 0.6
SecondaryInterpersonal Process of Care (IPC-18) at Protocol Completion - Communication Domain

The IPC is an 18-question questionnaire that asks participants about their experience with receiving care within a specific clinic (in this case the Duke Perinatal Durham Clinic). All IPC items use an identical set of response options: 1='never'; 2='rarely'; 3='sometimes'; 4='usually'; 5='always.' Item responses are averaged, not summed; thus, scores have a possible range of 1-5. All scales are scored so that higher scores indicate higher frequency of the labeled interpersonal process: Lack of clarity (higher scores are negative), Elicits concern (higher scores are positive), and Explain results (higher scores are positive).

Time frame:
protocol completion (approximately 1 year)
Reported as:
Mean · score on a scale
Interpersonal Process of Care (IPC-18) at Protocol Completion - Communication Domain
score on a scaleIntervention Arm: Weekly IP3 Text MessagesControl Arm: General Pregnancy Text Messages
Lack of clarity1.6 ± 0.61.6 ± 1.1
Elicits concern4.6 ± 0.64.7 ± 0.6
Explain results4.5 ± 0.64.6 ± 0.7
SecondaryInterpersonal Process of Care (IPC-18) at Protocol Completion - Decision Making Domain

The IPC is an 18-question questionnaire that asks participants about their experience with receiving care within a specific clinic (in this case the Duke Perinatal Durham Clinic). All IPC items use an identical set of response options: 1='never'; 2='rarely'; 3='sometimes'; 4='usually'; 5='always.' Item responses are averaged, not summed; thus, scores have a possible range of 1-5. All scales are scored so that higher scores indicate higher frequency of the labeled interpersonal process: Decision Making (higher scores are positive, denoting more collaborative decision making between the clinician and patient).

Time frame:
protocol completion (approximately 1 year)
Reported as:
Mean · score on a scale
Interpersonal Process of Care (IPC-18) at Protocol Completion - Decision Making Domain
score on a scaleIntervention Arm: Weekly IP3 Text MessagesControl Arm: General Pregnancy Text Messages
Interpersonal Process of Care (IPC-18) at Protocol Completion - Decision Making Domain4.4 ± 1.14.8 ± 0.4
SecondaryInterpersonal Process of Care (IPC-18) at Protocol Completion - Interpersonal Style Domain

The IPC is an 18-question questionnaire that asks participants about their experience with receiving care within a specific clinic (in this case the Duke Perinatal Durham Clinic). All IPC items use an identical set of response options: 1='never'; 2='rarely'; 3='sometimes'; 4='usually'; 5='always.' Item responses are averaged, not summed; thus, scores have a possible range of 1-5. All scales are scored so that higher scores indicate higher frequency of the labeled interpersonal process: Emotional support (higher scores are positive), Discrimination due to race/ethnicity (higher scores are negative), Disrespectful to office staff (higher scores are negative).

Time frame:
protocol completion (approximately 1 year)
Reported as:
Mean · score on a scale
Interpersonal Process of Care (IPC-18) at Protocol Completion - Interpersonal Style Domain
score on a scaleIntervention Arm: Weekly IP3 Text MessagesControl Arm: General Pregnancy Text Messages
Emotional support4.7 ± 0.54.8 ± 0.4
Discrimination due to race/ethnicity1.5 ± 0.71.3 ± 0.8
Disrespectful to office staff1.2 ± 0.31.1 ± 0.5
SecondaryChange in Maternal Social Support Scale (MSSS)

The MSSS is a six-question scale that quantifies a pregnant woman's social support. Social factors (lack of family support, low friendship network, lack of help from spouse/partner, conflict with spouse/partner, feeling controlled by spouse/partner, and feeling unloved by spouse/partner) are combined in a 6-item self-report 5-point Likert scale. The total possible score for the scale is between 6 and 30, with higher scores indicating increased support.

Time frame:
baseline to protocol completion (approximately 1 year)
Reported as:
Mean · score on a scale
Change in Maternal Social Support Scale (MSSS)
score on a scaleIntervention Arm: Weekly IP3 Text MessagesControl Arm: General Pregnancy Text Messages
Change in Maternal Social Support Scale (MSSS)0.1 ± 1.5-1.4 ± 2.4
SecondaryGestational Age at Delivery in Weeks
Time frame:
approximately 40 weeks
Reported as:
Mean · weeks
Gestational Age at Delivery in Weeks
weeksIntervention Arm: Weekly IP3 Text MessagesControl Arm: General Pregnancy Text Messages
Gestational Age at Delivery in Weeks34.0 ± 6.135.7 ± 3.5
SecondaryBirth Weight in Grams
Time frame:
approximately 40 weeks
Reported as:
Mean · grams
Birth Weight in Grams
gramsIntervention Arm: Weekly IP3 Text MessagesControl Arm: General Pregnancy Text Messages
Birth Weight in Grams2442.5 ± 1255.92607.9 ± 750.6
SecondaryNumber of Neonates Admitted to the Newborn Intensive Care Unit (NICU)
Time frame:
approximately 40 weeks
Reported as:
Count of units · Neonates
Number of Neonates Admitted to the Newborn Intensive Care Unit (NICU)
NeonatesIntervention Arm: Weekly IP3 Text MessagesControl Arm: General Pregnancy Text Messages
Number of Neonates Admitted to the Newborn Intensive Care Unit (NICU)54
SecondaryLength of Delivery Hospital Admission in Days
Time frame:
approximately 40 weeks
Reported as:
Median · days
Length of Delivery Hospital Admission in Days
daysIntervention Arm: Weekly IP3 Text MessagesControl Arm: General Pregnancy Text Messages
Length of Delivery Hospital Admission in Days2 (2 to 3)3 (2 to 3)

Adverse events

Collected over Approximately 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intervention Arm: Weekly IP3 Text Messages0/14 (0%)0/14 (0%)0/14 (0%)
Control Arm: General Pregnancy Text Messages0/16 (0%)0/16 (0%)0/16 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Intervention Arm: Weekly IP3 Text MessagesControl Arm: General Pregnancy Text MessagesTotal
Mean30.9 ± 5.332.1 ± 7.031.5 ± 6.2
Sex: Female, Male
Sex: Female, Male(Participants)Intervention Arm: Weekly IP3 Text MessagesControl Arm: General Pregnancy Text MessagesTotal
Female141630
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Intervention Arm: Weekly IP3 Text MessagesControl Arm: General Pregnancy Text MessagesTotal
Hispanic or Latino000
Not Hispanic or Latino141630
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intervention Arm: Weekly IP3 Text MessagesControl Arm: General Pregnancy Text MessagesTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American141630
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Intervention Arm: Weekly IP3 Text MessagesControl Arm: General Pregnancy Text MessagesTotal
United States141630
08

Study locations

1 site
  • Duke University
    Durham, North Carolina 27705, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jul 1, 2020
  • Informed consent form · Jan 21, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Apr 2021, 14 months.

Results were first posted in Nov 2022, 1 year 7 months after primary completion.

Of 753 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 14 months is below that.

Counting every sponsor, half of 775 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2019
First posted
Nov 4, 2019
StartActual
Feb 1, 2020
Primary completionActual
Apr 1, 2021
CompletionActual
Apr 1, 2021
Results first posted
Nov 2, 2022
Last update
Nov 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04149002
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Nov 4, 2019
Start date
Feb 1, 2020
Primary completion
Apr 1, 2021
Completion
Apr 1, 2021
Results posted
Nov 2, 2022
Last update
Nov 2, 2022

Study contacts

Sarahn Wheeler, MD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion